Developing active immunotherapy products (ACTIMPs) has long presented a unique bioanalytical bottleneck because therapeutic efficacy relies on complex host immune responses rather than straightforward direct activity. For years, drug developers have wrestled with static legacy testing expectations that fail to accommodate multi-antigen vectors, cellular matrices, or patient-specific neoantigen vaccines. The FDA’s new guidance outlines a risk-based roadmap to ensure a higher standard of biological characterization throughout product lifecycles. It presents a core commercial strategy to prevent clinical holds and accelerate market entry.
The guidance document highlights five key aspects of potency assessment.
- Sponsors should embark on a risk-based, phased approach to potency assurance by establishing functional assay designs early and validating them with early-stage material through commercial stage product. FDA acknowledges that early-stage investigational products, mostly, cannot meet full commercial validation standards. This builds directly on CBER’s Potency Assurance for Cellular and Gene Therapy Products guidance and ICH Q9(R1) Quality Risk Management. While phase-appropriate flexibility is granted under 21 CFR 312.23(a)(7), developers must establish functional assay designs early. Deficient potency strategies remain a primary trigger for clinical holds under 21 CFR 312.42(b).
- Aligning with ICH Q6B specifications, the FDA permits sponsors to rely on physicochemical lot release testing (e.g., sequence identity, peptide quantitation) for late-phase personalized products. However, this flexibility requires qualifying the end-to-end manufacturing process and scientifically validating the bio-informatics selection pipeline during Phase 1.
- To address therapies featuring multiple antigens, cell types, or separate vial formulations (such as separate peptide subsets mixed post-release), sponsors must demonstrate complete analytical coverage. Drawing from ICH Q5E comparability frameworks, if a single bioassay cannot capture all distinct mechanisms of action (MOAs), developers must implement complementary or orthogonal assays. For separate DP vials, release testing must occur individually prior to clinical site reconstitution.
- Adjuvants must prove they do not compromise safety or potency. Furthermore, non-functional reporter genes or irrelevant vector epitopes are explicitly discouraged due to off-target immune risks. Any change to an established bio-informatics pipeline is categorized as a major CMC change under 21 CFR 312.31 and 21 CFR 601.12, requiring rigorous comparability assessments.
- For living cells, irradiated tumor products, or lysates, potency testing must extend beyond simple cell counts. Building on cell therapy CGMPs (21 CFR Parts 210/211/600), membrane integrity and cell viability are codified as non-negotiable potency-related Critical Quality Attributes (CQAs). For genetically modified irradiated cells (e.g., GM-CSF secreting lines), assays must measure both expression levels and biological activity, while lysates require protein profiling to maintain lot-to-lot consistency.
The FDA’s updated guidance marks a major leap forward in harmonizing regulatory science with the realities of modern active immunotherapies. By defining clear pathways for personalized neoantigens and multi-component vectors, CBER gives developers the leverage needed to streamline early clinical trials without sacrificing quality control. However, achieving long-term success requires early alignment across bio-informatics qualification, reagent supply chains, and orthogonal assay design. Sponsors who proactively integrate these CQA principles into their CMC strategy will successfully navigate comparability shifts and accelerate regulatory approvals. Ultimately, taking a thoughtful approach to potency assurance ensures that groundbreaking science translates into reliable, life-saving patient therapies.
